

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 223 225 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
17.07.2002 Bulletin 2002/29

(51) Int Cl.7: **C12Q 1/68**

(21) Application number: **01200057.6**

(22) Date of filing: **10.01.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventor: **Herrewegh, Arnold Aloysius Philomena
Maria
3607 KE Maarssen (NL)**

(71) Applicant: **STICHTING NEDERLANDS INSTITUUT
VOOR ZUIVELONDERZOEK
6710 BA Ede (NL)**

(74) Representative: **Jorritsma, Ruurd et al
Nederlandsch Octrooibureau
Scheveningseweg 82
P.O. Box 29720
2502 LS Den Haag (NL)**

(54) **Detection of mycobacterium avium ssp paratuberculosis**

(57) The present invention relates to methods for the PCR-based detection of nucleic acids from *Mycobacterium avium* ssp. *paratuberculosis* (*Mycobacterium paratuberculosis*), in biological samples such as milk. The oligonucleotide primers to be used in the method of the invention are designed so as to improve the specif-

icity of detection of *Mycobacterium avium* ssp. *paratuberculosis* by avoiding detection of related environmental *Mycobacteria*. The sensitivity of detection is improved by using an optimized procedure for extraction of DNA from milk and by using a nested PCR method.

6, 11, 12, 13

3/17/2003

7/17/2002

July 2002 - March 2003

EP 1 223 225 A1

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 223 225 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
17.07.2002 Bulletin 2002/29

(51) Int Cl.7: **C12Q 1/68**

(21) Application number: **01200057.6**

(22) Date of filing: **10.01.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventor: **Herrewegh, Arnold Aloysius Philomena
Maria**
3607 KE Maarssen (NL)

(71) Applicant: **STICHTING NEDERLANDS INSTITUUT
VOOR ZUIVELONDERZOEK**
6710 BA Ede (NL)

(74) Representative: **Jorritsma, Ruurd et al**
Nederlandsch Octrooibureau
Scheveningseweg 82
P.O. Box 29720
2502 LS Den Haag (NL)

(54) **Detection of mycobacterium avium ssp paratuberculosis**

(57) The present invention relates to methods for the PCR-based detection of nucleic acids from *Mycobacterium avium* ssp. *paratuberculosis* (*Mycobacterium paratuberculosis*), in biological samples such as milk. The oligonucleotide primers to be used in the method of the invention are designed so as to improve the specif-

icity of detection of *Mycobacterium avium* ssp. *paratuberculosis* by avoiding detection of related environmental *Mycobacteria*. The sensitivity of detection is improved by using an optimized procedure for extraction of DNA from milk and by using a nested PCR method.

EP 1 223 225 A1

DescriptionField of the Invention

- 5 [0001] The present invention relates to the PCR-based detection of nucleic acids from *Mycobacterium avium* ssp. *paratuberculosis* (*Mycobacterium paratuberculosis*), in biological samples such as milk.

Background of the Invention

- 10 [0002] Paratuberculosis, or Johne's disease, is a chronic enteritis of ruminants which is caused by *Mycobacterium paratuberculosis*. Prevalance in cattle worldwide ranges from 0 to 40% and the disease also affects other ruminants such as sheep and goats. More recently, *M. paratuberculosis* has also been implicated in Crohn's disease (regional ileitis) of humans, which has further increased the need to control the spread of *M. paratuberculosis*.

- 15 [0003] Control of Johne's disease has been seriously hampered by inadequate and time consuming diagnostic procedures. *M. paratuberculosis* is an intracellular pathogen which replicates in macrophages in the lamina propria of the intestines and is shed into the feces during disease. Initially, diagnosis involved culture of *M. paratuberculosis* from feces. However, *M. paratuberculosis* requires complex culture conditions for growth *in vitro* and is extremely slow growing. Primary isolation of the organism from feces would usually take 6 - 12 weeks. In addition, infected animals may only intermittently shed the microorganism, as a result of which false negatives will occur. Similarly, diagnosis on the basis of immunological techniques has been hampered by false negatives, and also by false positive results due to prior immunological exposure or cross-reactivity of the test to related environmental mycobacteria.

- 20 [0004] More recently, DNA-based techniques have been developed for the detection of *M. paratuberculosis*. EP 0 288 306 discloses DNA probes for the detection of mycobacteria based on DNA sequences derived from the mycobacterial insertion sequence IS 900 (also referred to as ISM1). IS 900 was identified in a clone derived from genomic library prepared from a human Crohn's disease isolate of *M. paratuberculosis*. The IS 900 sequence is found to be repeated 15 to 20 times in the genome of *M. paratuberculosis*. EP 0 288 306 further discloses the DNA sequence of IS 900, methods for identifying and differentiating mycobacteria using IS 900-based probes in DNA fingerprinting and suggests using IS 900 sequences in methods for detecting mycobacteria using polymerase chain reaction (PCR). However, EP 0 288 306 does not disclose any IS 900-based primers for this purpose.

- 30 [0005] Vary et al. (1990; J. Clin. Microbiol. 28: 933-937) disclose direct and specific detection of *M. paratuberculosis* in feces from cattle with Johne's disease using primers based on IS 900 sequences in a PCR. The PCR test has a sensitivity at least equal to that routinely obtained in the conventional culture techniques.

- 35 [0006] Millar et al. (1995; Anal. Biochem. 226: 325-330) combine a solid phase hybridization capture system for the enrichment of *M. paratuberculosis* target sequences with IS 900 based PCR to increase the sensitivity of the reaction to 10-100 copies of *M. paratuberculosis* per gram of feces.

- 40 [0007] With the implication of *M. paratuberculosis* in Crohn's disease in human the need for tests for detection of *M. paratuberculosis* in cow's milk for human consumption has arisen. Millar et al. (1996; Appl. Environ. Microbiol. 62: 3446-3452) disclose an IS 900-based PCR procedure for detection of *M. paratuberculosis* in both raw and pasteurized cow's milk. The sensitivity of the procedure is estimated to lie in the range of 200 - 300 *M. paratuberculosis* bacilli per ml of milk.

- 45 [0008] A problem with the IS 900-based PCR detection of *M. paratuberculosis* is that IS 900 is part of a family of DNA insertion sequences in the actinomycetes. Non-pathogenic environmental mycobacteria such as *M. avium* ssp. *avium* are known to contain insertion sequences IS 901 and IS 1613 both of which have a high sequence homology with the IS900 sequence of *M. paratuberculosis*. Consequently, PCR primers may not be able to distinguish between these related insertion sequences, particularly if their 3'-end is homologous to the non-IS 900 insertion sequences. This will compromise the selectivity of IS 900-based PCR detection of *M. paratuberculosis* and may lead to false positive results.

- 50 [0009] Thus, there is still a need for an IS 900-based PCR test for the detection of *M. paratuberculosis* with improved sensitivity and improved specificity.

Description of the InventionDefinitions

- 55 [0010] The term "oligonucleotide" as used herein includes linear oligomers of natural or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, .alpha.-anomeric forms thereof, polyamide nucleic acids, and the like, capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions (e.g. nucleoside-to-nucleoside), such as Watson-Crick type of base pairing, Hoogsteen or reverse Hoog-

steen types of base pairing, or the like. Usually monomers are linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g. 3-4, to several hundreds of monomeric units, although usually no more than 100 monomeric units. Whenever an oligonucleotide is represented by a sequence of letters, such as "ATGCCTG," it will be understood that the nucleotides are in 5'→3' order from left to right and that "A" denotes deoxyadenosine, "C" denotes deoxycytidine, "G" denotes deoxyguanosine, and "T" denotes thymidine, unless otherwise noted. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphorose-

lenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate and the like. [0011] The term "primer" as used herein refers to an oligonucleotide whether occurring naturally as in a purified restriction digest or produced synthetically by chemical and/or enzymatic synthesis, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, i.e., in the presence of nucleotide and an agent for polymerization such as DNA polymerase and at a suitable temperature and pH. The primer is preferably single-stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the agent for polymerization. The exact lengths of the primers will depend on many factors, including temperature and source of primers. Oligonucleotide primers will typically contain 15-30 or more nucleotides, although in the context of the present invention primers will preferably contain 18-24 nucleotides.

[0012] Unless specified otherwise, the conventional notation used herein portrays polynucleotides as follows: the left-hand end of single-stranded polynucleotide sequences is the 5' end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. A location in a polynucleotide is referred to as "upstream" of a reference point in that polynucleotide if that location is closer to the 5'-end of the polynucleotide with respect to the reference point. A location in a polynucleotide is referred to as "downstream" of a reference point in that polynucleotide if that location is closer to the 3'-end of the polynucleotide with respect to the reference point. "Polymerase Chain Reaction" or "PCR" is a rapid procedure for in vitro enzymatic amplification of a specific DNA segment. The DNA to be amplified is denatured by heating the sample. In the presence of DNA polymerase and excess deoxynucleotide triphosphates, oligonucleotides that hybridize specifically to the target sequence prime new DNA synthesis. One round of synthesis results in new strands of indeterminate length which, like the parental strands, can hybridize to the primers upon denaturation and annealing. The second cycle of denaturation, annealing and synthesis produces two single-stranded products that together compose a discrete double-stranded product, exactly the length between the primer ends. This discrete product accumulates exponentially with each successive round of amplification. Over the course of about 20 to 45 cycles, many million-fold amplification of the discrete fragment can be achieved. PCR protocols are well known in the art, and are described in standard laboratory textbooks, e.g. Ausubel et al., "Current Protocols in Molecular Biology", John Wiley & Sons, Inc. (1995).

[0013] The melting temperature (indicated as " T_m ") of a DNA molecule, herein usually an oligonucleotide, is understood to mean the temperature at which the transition of double-stranded DNA to single-stranded DNA is halfway complete during thermal denaturation. The T_m of an oligonucleotide of known sequence may be calculated using the Nearest Neighbor Algorithm for T_m , formula:

$$T_m = \frac{\Delta H^\circ}{\Delta S^\circ + (R \times \ln(C_T))} - 273.15$$

wherein ΔH° is the enthalpy and ΔS° is the entropy for helix formation, R is the molar gas constant (1.987 cal/K-mol), and C_T is the total primer concentration (Beslauer, K.J., Frank, R., Blocker, H. and Marky, L.A. 1986. Proc.Natl.Acad. Sci. 83:3746-3750).

[0014] "*Mycobacterium paratuberculosis*" has recently been (re)classified as a subspecies of *Mycobacterium avium* and consequently has been renamed as *Mycobacterium avium* ssp. *paratuberculosis* (Thorel, MF, Krichevsky, M., Levy-Frebault V.V. (1990) Int. J. Syst. Bacteriol. 40:254-260). It is, therefore, understood that the term "*M. avium* ssp. *paratuberculosis*" as used herein, equally refers to all bacteria (previously) referred to as *M. paratuberculosis*.

[0015] In a first aspect the invention relates to oligonucleotides corresponding in sequence to a part of SEQ ID NO. 1 (i.e. IS 900), or to its complementary sequence. The oligonucleotides may be used as primers in PCR-based detection of *M. avium* ssp. *paratuberculosis*. For improved specificity and sensitivity of the PCR detection, the oligonucleotides of the invention further comply with one or more of the following criteria: (a) the length of the oligonucleotides is 14 to 30 nucleotides, preferably 18 to 24 nucleotides; (b) the G/C content of the oligonucleotides is 37% to 70%; (c) the melting temperature of the oligonucleotides ranges from 55 to 65 °C; (d) the oligonucleotides do not contain more than 5 contiguously repeated bases of the same type, e.g. the oligonucleotides do not contain more than 5 consecutive adenines; (e) the oligonucleotides do not contain more than 7 contiguous residues selected from the group consisting

of G and C residues; (f) the total number of G and C residues in the oligonucleotides ranges from 9 to 13. Thus, e.g. an oligonucleotide of 14 nucleotides will comprise no more than 9 G and/or C residues (limited by the 70% G/C) and an oligonucleotide of 30 nucleotides will comprise no more than 13 G and/or C residues (limited by the number 13 which in this case corresponds to 43% G/C); (g) the oligonucleotides have at least two mismatches with SEQ ID NO. 2 (i.e. IS 901) and with SEQ ID NO. 3 (i.e. IS 1631), of which at least one mismatch with each SEQ ID NO. 2 and with SEQ ID NO. 3 occurs in the three most extreme nucleotides at the 3'-end of the oligonucleotides. Preferably, the oligonucleotides have at least four mismatches with SEQ ID NO. 2 and with SEQ ID NO. 3, of which at least two mismatches with each SEQ ID NO. 2 and SEQ ID NO. 3 occur in the three most extreme nucleotides at its 3'-end, of which at least one mismatch with either SEQ ID NO. 2 or SEQ ID NO. 3 occurs at the most extreme nucleotide at its 3'-end. More preferably, the oligonucleotides have at least five, six, seven or eight mismatches with SEQ ID NO. 2 and with SEQ ID NO. 3, of which at least two mismatches, with both of each SEQ ID NO. 2 and SEQ ID NO. 3, occur in the three most extreme nucleotides at its 3'-end, of which at least one mismatch with either SEQ ID NO. 2 or SEQ ID NO. 3 occurs at the most extreme nucleotide at its 3'-end. In a preferred embodiment of the invention, the oligonucleotide of the invention has a nucleotide sequence selected from the group consisting of SEQ ID NO. 4 - SEQ ID NO. 38. Figure 1 presents an alignment of the DNA sequences of IS 900 (SEQ ID NO. 1), IS 901 (SEQ ID NO. 2) and IS 1631 (SEQ ID NO. 3). Using this sequence comparison the skilled person will be capable of designing other oligonucleotides according to the invention.

[0016] A further aspect of the invention relates to a method for detection of *M. avium* ssp. *paratuberculosis* in a sample by means of amplification and detection of *M. avium* ssp. *paratuberculosis*-specific nucleic acids by PCR. The method is applicable to any kind of sample but will typically be performed on samples obtained from a human or animal subject, such as e.g. blood, feces, urine, saliva, tissue, or milk. The sample may be obtained from more than one subject, e.g. in the dairy industry sample may be taken from batches of pooled milk obtained from many different animals. The method will usually comprise the step of preparing the sample for PCR, which may involve extraction of template DNA from the sample. A variety of methods for sample preparation for PCR are known per se to the skilled person and are described in Innis et al., "PCR protocols" Academic Press (1990) and in Ausubel et al., "Current Protocols in Molecular Biology", John Wiley & Sons, Inc. (1995). A very simple method for PCR sample preparation consists of no more than mixing or suspending a sample in an appropriate amount of (demineralized) water and heating the sample for at least 1 minute, preferably 3 to 5 minutes, at a temperature of at least 90°C, preferably at least 95°C or 100°C, and, optionally, centrifuging the sample to remove any insoluble debris (e.g. for 3 minutes in a microcentrifuge). The Examples herein provide a method for PCR sample preparation which is optimized for highly sensitive PCR-based detection of DNA in milk, e.g. to be applied for PCR-based detection of the presence of (pathogenic) micro-organisms, such as *M. avium* ssp. *paratuberculosis*, in milk.

[0017] In the method for detection of *M. avium* ssp. *paratuberculosis* in a sample a PCR is performed on the sample, wherein a first and a second oligonucleotide of the invention are used as PCR primers, of which the first oligonucleotide is of the same orientation as SEQ ID NO. 1 (sense) and is located upstream of the second oligonucleotide with respect to SEQ ID NO. 1 and of which the second oligonucleotide is complementary to SEQ ID NO. 1 (antisense). Preferably, the first and second oligonucleotides are chosen such that the resulting PCR product is less than 1000 bp, preferably less than 750 bp or 500 bp but preferably more than 50 bp, preferably more than 75 bp. Typical combinations of first and second oligonucleotides are e.g. a first oligonucleotide selected from any one of SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, and a second oligonucleotide selected from any one of SEQ ID NO. 24, SEQ ID NO. 25, SEQ ID NO. 26, SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 29, SEQ ID NO. 30.

[0018] The PCR conditions are generally well known in the art (see e.g. Innis et al., "PCR protocols" Academic Press (1990) and in Ausubel et al., "Current Protocols in Molecular Biology", John Wiley & Sons, Inc. (1995)). Usually at least 25 cycles are performed, preferably at least 30, 35 or 40 cycles but in general no more than 45 cycles are required. As a typical but non-limiting example, one cycle may consist of 25 seconds denaturation at 94°C, followed by 20 seconds annealing at a temperature which is 5°C below the T_m of the primer with the lowest T_m, followed by 50 seconds of polymerization (primer extension) at 72°C.

[0019] Buffer conditions, i.e. type of buffer, pH, triphosphate nucleotide concentrations and mono- and di-valent cation concentration are well known in the art from *inter alia* the above referenced textbooks. Similarly, polymerases suitable for PCR are well known in the art and include the *Taq* polymerase as used herein as well as other polymerases from both meso- and thermo-philic organisms such as DNA polymerase I - Klenow fragment, Vent™ and Deep-Vent™ DNA polymerases, and *Tfi* DNA polymerase.

[0020] In a preferred aspect of the invention a so-called "nested PCR" is applied for the detection of *M. avium* ssp. *paratuberculosis* in order to further improve both the sensitivity and the specificity of the PCR. This aspect of the invention relates to a method for PCR-based detection of *M. avium* ssp. *paratuberculosis*, wherein the PCR product obtained in the first stage PCR with the first and second oligonucleotides is used as template in a second stage PCR, in which a third and a fourth oligonucleotide are used as primers. The third oligonucleotide is of the same orientation

as SEQ ID NO. 1 and is located downstream of the first oligonucleotide but upstream of the second oligonucleotide and upstream of the fourth oligonucleotide with respect to SEQ ID NO. 1. The fourth oligonucleotide is complementary to SEQ ID NO. 1 and is located upstream of the second oligonucleotide with respect to SEQ ID NO. 1. Typical combinations of first, second, third and fourth oligonucleotides are e.g. a first oligonucleotide selected from any one of SEQ ID NO. 4, SEQ ID NO. 6, or SEQ ID NO. 7, a second oligonucleotide selected from any one of SEQ ID NO. 24, SEQ ID NO. 28, or SEQ ID NO. 29, a third oligonucleotide selected from any one of SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, and a fourth oligonucleotide selected from any one of SEQ ID NO. 25, SEQ ID NO. 26, or SEQ ID NO. 27. Table 1 provides an overview of oligonucleotides SEQ ID NO. 4- SEQ ID NO. 38, including the position and orientation of the oligonucleotides with respect to SEQ ID NO. 1, allowing the skilled person to select other combinations of four oligonucleotides suitable for nested PCR detection of *M. avium* ssp. *paratuberculosis*. Similarly, based on the DNA sequence comparison of Figure 1, the skilled person may design other oligonucleotides according to the invention which in combination are suitable for nested PCR detection of *M. avium* ssp. *paratuberculosis*.

[0021] Another aspect of the invention relates to the detection and/or identification of the amplified DNA fragment, if any, in the first- and second-stage PCRs. The amplified product may be directly or indirectly detected by incorporation of an appropriate visualizing label, as for example, a radioactive, calorimetric, fluorometric (ethidium bromide) or luminescent signal, or the like. Identification of the amplification products, as being derived from the *M. avium* ssp. *paratuberculosis* IS 900 insertion sequence (SEQ ID NO. 1), may be accomplished by any one of several methods known in the art to identify amplified nucleotide sequences. These methods include, but are not limited to, determination of size, restriction enzyme digestion pattern, subsequent cloning of amplification products, Southern blot hybridization with an oligonucleotide probe internal to the nucleotide sequence being amplified, or DNA sequencing. The amplified DNA products are optionally separated from the reaction mixture and then analyzed. The amplified gene sequences may be visualized, for example, by separating the gene sequences from undesirable side-products and unreacted reagents by electrophoresis in an agarose or polyacrylamide gel, by HPLC separation in an ion exchange column or size exclusion column, by Capillary Electrophoresis as described by Kuypers et al. (1994) J. Chromatogr. B, 660:271, or by a Enzyme Linked Oligonucleotide Sorbent Assay (ELOSAs technique) as described by Luneberg et al. (1993) J. Clin. Microbiol. 31:1088 and Katz et al. (1993) Am. J. Vet. Res., 54:2021, and other like techniques known and used in the art. The methods of the invention for detection of *M. avium* ssp. *paratuberculosis* are preferably used to detect the presence or absence of this bacterium in milk samples, of which preferably sample of milk intended for human (or animal) consumption such as bovine, ovine, caprine, equine or human milk or colostrum.

[0022] The present invention also relates to of "kits" containing elements for detecting *M. avium* ssp. *paratuberculosis*. Such a kit may comprise a carrier to receive therein one or more containers, such as tubes or vials. Unlabeled or detectable labeled oligonucleotides of the invention, e.g. to be used as primers, may be contained in one or more of the containers. The oligonucleotides may be present in lyophilized form, or in an appropriate buffer. One or more enzymes or reagents for use in PCR reactions may be contained in one or more of the containers. The enzymes or reagents may be present alone or in admixture, and in lyophilized form or in appropriate buffers. The kit may also contain any other component necessary for carrying out the present invention, such as buffers, agents for extraction of DNA (e.g. from milk), enzymes, pipettes, plates, nucleic acids, nucleoside triphosphates, filter paper, gel materials, transfer materials, and autoradiography supplies. Such other components for the kits of the invention are known per se. Preferably a kit comprises at least two oligonucleotides according to the invention, of which a first oligonucleotide is of the same orientation as SEQ ID NO. 1 and is located upstream from a second oligonucleotide with respect to SEQ ID NO. 1 and wherein the second oligonucleotide is complementary to SEQ ID NO. 1. A more preferred kit further comprises a third and a fourth oligonucleotide according to the invention, of which the third oligonucleotide is of the same orientation as SEQ ID NO. 1 and is located downstream of the first oligonucleotide, upstream of the second oligonucleotide and upstream of the fourth oligonucleotide with respect to SEQ ID NO. 1, and of which the fourth oligonucleotide is complementary to SEQ ID NO. 1.

[0023] The following Examples serve to illustrate the invention and should by no means be construed so as to limit the scope of the invention.

Examples

Example I: Procedure for the extraction of nucleic acids from milk

[0024] To 25 ml of raw milk was added 5 ml 1-propanol, 5 ml 25% ammonia, 5 ml petroleum-ether, 5 ml diethylether and 10^6 colony forming units of *Lactobacillus plantarum* (or any other non-sporeforming Gram-positive bacterium species). The milk with additions were thoroughly mixed and centrifuge for 20 min at 4500 rpm in a table centrifuge (*Lactobacilli* are added to act as a carrier for the minute amounts of *Mycobacteria* present in milk). Subsequently, the fatty upperlayer and the supernatant are removed, the pellet is resuspended in 1 ml bi-distilled water and transferred to a 1.5 ml reaction tube and centrifuged for 5 min at 3.000 rpm in a microcentrifuge. The supernatant is removed and 300

µl of a 6% Chelex 100 suspension in water is added and incubated for 30 min at 56 °C. 300 µl of GTC-buffer (5 M guanidinium thiocyanate (CH₅N₃CHNS) in 100 mM Tris/HCl pH 8.0) is added and heated for 15 min at 100 °C, followed by freezing at -20 °C, followed by another heating at 100 °C for 10 min. After centrifugation for 5 min at 12000 rpm in a microcentrifuge, 500 µl supernatant is transferred to a new reaction tube and 500 µl isopropanol is added followed by an incubate of 2 hours at -20 °C and subsequently centrifugation at 4 °C for 30 min at 14.000 rpm in a microcentrifuge. The supernatant is removed and the DNA pellet is washed in 70% ethanol, dried and dissolved in 20 µl H₂O. This DNA solution is used as a template for PCR amplification.

Example II: Nested PCR for the detection of *M. avium* ssp. *paratuberculosis* in milk

[0025] For nested-PCR amplification of *M. avium* ssp. *paratuberculosis*, the four primers IS900-01 (SEQ ID NO: 4 = CTTACCTTTCTTGAAGGGTGTTC), IS900-02 (SEQ ID NO 5 = GTATGGCTTTCATGTGGTTGCT), IS900-03 (SEQ ID NO: 25 = TAACCGTCATTGTCCAGATCAAC) and IS900-04 (SEQ ID NO: 24 = GTCGTTAATAACCATGCAGTAATG) were used.

[0026] First-PCR: to a 0.5 ml PCR tube was added, 5 µl 10x PCR buffer (100 mM Tris-HCl, 500 mM KCl, pH 9.0), 200 nM primer IS900-01, 200 nM primer IS900-04, 200 µM dATP, 200 µM dCTP, 200 µM dGTP, 200 µM dTTP, 2.5 mM MgCl₂, 5 µl DNA template, 1.5 units Taq polymerase, H₂O to 50 µl. First-PCR programme: 3 min preincubation at 90 °C followed by 40 cycli of 25 sec at 94 °C, 20 sec at 60 °C, 50 sec at 72 °C. The reaction mixture of the first-PCR (which reveals a product of 302 basepairs) was used as template in the nested-PCR.

[0027] Second (nested)-PCR: to a 0.5 ml PCR tube was add, 5 µl 10x PCR buffer (100 mM Tris-HCl, 500 mM KCl, pH 9.0), 200 nM primer IS900-02, 200 nM primer IS900-03, 200 µM dATP, 200 µM dCTP, 200 µM dGTP, 200 µM dTTP, 1.5 mM MgCl₂, 5 µl first PCR template, 1.5 units Taq polymerase, H₂O to 50 µl. Nested-PCR programme: 40 cycli of 25 sec at 94 °C, 20 sec at 60 °C, 50 sec. at 72 °C. Positive PCR samples reveal a band of 159 basepairs.

Example III: Sensitivity of the nested PCR assay

[0028] To determine the sensitivity of the nested PCR assay, 5 µl of plasmid pMD2 solution in water, containing 1, 10, 100, 1000, 10.000, and 100.000 copies of pMD2, respectively, was used as a template in the first PCR, followed by the second PCR. Plasmid pMD2 contains the 335 most 5' basepairs of IS900 cloned into pUC21. 10 µl amplified PCR product was run on a 2% agarose gel. With the first PCR, as little as 100 copies of pMD2 could be detected, corresponding to 100 copies of IS900. With the nested PCR, as little as 1 copy of pMD2 could be detected, corresponding to 1 copy of IS900.

Example IV: Detection of *M. avium* ssp. *paratuberculosis* in milk from infected cows.

[0029] The efficacy of the nested PCR to detect *M. avium* ssp. *paratuberculosis* in milk was investigated. DNA was extracted from 25 ml of raw milk obtained from nine cows having a *M. avium* ssp. *paratuberculosis* infection and from ten cows free of *M. avium* ssp. *paratuberculosis*. The purified DNA was used as template in the nested PCR assay with primers IS900-01, IS900-02, IS900-03 and IS900-04. The PCR product of the second PCR was analyzed on a 2% agarose gel. The nine milk samples obtained from the cows with *M. avium* ssp. *paratuberculosis* of 159 bp. The 10 milk samples from uninfected cows revealed no amplification product..

Table 1.

<i>M. paratuberculosis</i> primers and their position and orientation with respect to IS900								
Sequence	SEQ ID NO.	Length	A	C	G	T	Position	Orientation
IS900	1	1451	252	498	453	248	1 - 1451	SENSE
P-IS01	4	23	3	5	5	10	3 - 25	SENSE
P-IS02	5	22	2	3	7	10	66 - 87	SENSE
P-IS03	25	23	7	7	3	6	202 - 224	ANTI-SENSE
P-IS04	24	24	7	5	4	8	281 - 304	ANTI-SENSE
P-IS05	6	22	3	4	7	8	6 - 27	SENSE
P-IS06	7	22	2	4	8	8	7 - 28	SENSE
P-IS07	8	23	1	3	8	11	70 - 92	SENSE
P-IS08	9	23	1	3	8	11	71 - 93	SENSE
P-IS09	10	23	1	3	8	11	72 - 94	SENSE

EP 1 223 225 A1

Table 1. (continued)

<i>M. paratuberculosis</i> primers and their position and orientation with respect to IS900								
Sequence	SEQ ID NO.	Length	A	C	G	T	Position	Orientation
P-IS10	11	21	1	4	8	8	190 - 210	SENSE
P-IS11	12	21	1	4	8	8	191 - 211	SENSE
P-IS12	13	24	6	4	7	7	203 - 226	SENSE
P-IS13	14	21	4	4	8	5	228 - 248	SENSE
P-IS14	15	21	3	5	7	6	230 - 250	SENSE
P-IS15	16	22	7	4	6	5	290 - 311	SENSE
P-IS17	17	22	6	5	7	4	292 - 313	SENSE
P-IS18	18	20	2	4	8	6	349 - 368	SENSE
P-IS19	19	20	2	4	8	6	350 - 369	SENSE
P-IS20	20	18	4	7	5	2	409 - 426	SENSE
P-IS21	21	19	5	7	5	2	544 - 562	SENSE
P-IS22	22	20	4	7	6	3	629 - 648	SENSE
P-IS23	23	20	4	8	4	4	638 - 657	SENSE
P-IS24	26	22	6	4	8	4	208 229	ANTI-SENSE
P-IS25	27	22	6	3	9	4	209 - 230	ANTI-SENSE
P-IS26	28	24	7	4	5	8	283 - 306	ANTI-SENSE
P-IS27	29	20	6	6	6	2	298 - 317	ANTI-SENSE
P-IS28	30	20	2	4	8	6	349 - 368	ANTI-SENSE
P-IS29	31	19	2	3	9	5	361 - 379	ANTI-SENSE
P-IS30	32	21	3	5	6	7	468 - 488	ANTI-SENSE
P-IS31	33	18	4	7	4	3	560 - 577	ANTI-SENSE
P-IS32	34	20	4	6	6	4	616 - 635	ANTI-SENSE
P-IS33	35	20	3	6	6	5	647 - 666	ANTI-SENSE
P-IS34	36	22	6	9	3	4	778 - 799	ANTI-SENSE
P-IS35	37	18	2	6	7	3	819 - 836	ANTI-SENSE
P-IS36	38	18	3	8	5	2	862 - 879	ANTI-SENSE

SEQUENCE LISTING

5 <110> Stichting Nederlands Instituut voor Zuivelonderzoek

<120> Detection of Mycobacterium paratuberculosis nuclei acids

10 <130> M.paratuberculosis

<140>

<141>

<160> 38

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 1451

<212> DNA

20 <213> Mycobacterium paratuberculosis

<400> 1

tccttacctt	tcttgaagg	tggtcgggc	cgtcgcttag	gcttcgaatt	gcccagggac	60
gtcgggtatg	gctttcatgt	ggttgctgtg	ttggatggcc	gaaggagatt	ggccgcccgc	120
ggtcccgcga	cgactcgacc	gctaattgag	agatgcgatt	ggatcgctgt	gtaaggacac	180
25 gtcggcggtg	tcgtctgctg	ggttgatctg	gacaatgacg	gttacggagg	tggttgtggc	240
acaacctgtc	tgggcgggcg	tggaacggcg	taaggccgac	cattactgca	tggttattaa	300
cgacgacgcg	cagcgattgc	tctcgacgcg	ggtggccaac	gacgaggccg	cgctgctgga	360
ggtgattgcg	gcggtgacga	cgttggccga	tggaggcgag	gtcacgtggg	cgatcgacct	420
caacgcccgc	ggcgccgctg	tgctgatcgc	cttgctcctc	gctgcccggc	agcggtgctg	480
30 ttatatcccg	ggcgccacgg	tccatcacgc	cgcggttagt	taccgcccgc	aaggcaagac	540
cgacgcaaaa	gacgctgcca	tcacgcccga	tcaggcccgc	atgcgccacg	acttgcagcc	600
tctgcgcgcc	ggcgatgaca	tcgcagtcga	gctgcgcctc	ctgaccagcc	gacgttccga	660
tctggtggct	gatcggaacc	ggcgatcgca	accgaatgcg	cgcccagctg	ctggaatact	720
ttcggcgctg	gaacgcgcct	tcgaactaaa	caagagccgt	gccgcgctga	tcctgcttac	780
tggtctacaa	actcccagcg	cgctgcgcag	cgccggtggc	gctcgagtag	ccgcgttctt	840
35 gcgtaaacgc	aaggcccgcg	acgccgatac	cgtcgcagcc	accgcgctgc	aggccgctaa	900
cgcccaacac	agcatcgtgc	ccggccaaca	actggcgccc	actgtggtgg	ccgcctggc	960
caaggagggtg	atggccctcg	acaccgaaat	cgcgacaccc	gacgcgatga	tcgaggagcg	1020
atttcgcccgc	caccgccacg	ccgaaatcat	cctgagcatg	cccggattcg	gcgtcatcct	1080
gggcgctgag	ttcctcgccg	ccaccggcgg	ggacatggcc	gcattcgctt	ccgccgaccg	1140
cctcgccggc	gtcgccggcc	tggcgcgggt	accacgagat	tcgggcgcga	tcagcggaac	1200
40 cctcaaaccgc	ccccgacgct	acgaccggcg	cctgctgcgc	gcctgctacc	tgtcggcctt	1260
ggtcagcatc	cgcaaccgac	cctcctcgcg	cacctactac	gaccgaaaac	gcaccgaagg	1320
aaaacgcccac	acccaagccg	tcctcgccct	ggcccgcgcg	cgccctcaacg	tcctgtgggc	1380
catgctgcgc	gaccacgctg	tctaccaccc	cgcaaccact	accgcggcgg	cttgacaacg	1440
tcattgagaa	t					1451

45 <210> 2

<211> 1472

<212> DNA

<213> Mycobacterium avium

50 <400> 2

ttccttaggg	ttgaagggtg	ctgggattgg	atgtcctgga	tgcccaggac	ggtgggggtg	60
ggctaattgt	ttgttgcaac	ggttggtgct	tgaaaggaat	ggccgccttg	ccgttttgga	120
cggtcctggc	cactgattga	gatctgacgc	gtactcgatg	acgctgctct	aaggacctgt	180
tgccgggggt	gtccgcgggg	actgcgacga	caggagtagc	ggtatggccg	aaccgaccg	240
55 agtgtgggtg	ggtatcgacg	tcggtaagtc	cactcatcat	gcgtgcgcga	tcgatgacac	300

cggaaggtg gtgtggtcga agaaaatccc gaacgaacag gccgcgatcg aagacctgat 360
 cgcccaggcg ggcggtattg ctaaccacgt ggtgtggcg atcgatttga cctcgcgcg 420
 ggcggcgctg ctgatcgccg tactgtctgag cgcgaaagcc gaggtggtgt atgtgccggg 480
 5 ccgcacgggtt aacacgatga gtcattgcgtt ccgcggcgaa ggcaagaccg acgccaaga 540
 cgcgcggtga atcgccgaaa ccgctcggca ccgacgagat ctgtccccgg tcgtaccgg 600
 cgaagacctg gttgccgaat tgcggtcgct gaccgcatac cggtcggatc tgatggctga 660
 ctgggtgcca ggctgaacc gcgtgcgtc gatgtcacc gccatcttcc ctgtcttga 720
 agctgcgttc gactactcca ccgcgcgcc gttgatctg gtatccgcta tgtgactcc 780
 10 ggccgaaatc cggtcggcaa aaagagctgg cgtgatcaag cacttcgga aaaaccggcg 840
 atggcccaac aacatcgaca cgatcgccga caaggcctc gccgcggcag caggccagat 900
 aatcaccctt cccggcgaa cgggaaccgc cgcgtctatc aagcaactcg cagcacggct 960
 gctggacttg gatcgcgaga tcaaggacat cgataagcaa atcaccaaca aatttcgtga 1020
 gcatccacgc gccgccatca tcgagtcgat gcccgccatg gggccacacc tggcgctga 1080
 gttcctctga atcaccggcg gcaacatggc cgccttcacc aaccccgcc gactggcatc 1140
 15 gttgcggga ttggtaccgg tcccacgca ttcggcgct atcaccggca atctgcatc 1200
 gcccaagcga tacaaccggc gctgcgcg cgtgttctac ctgcgcgcc tgtccagct 1260
 caagatcgaa ggtccctcgc gggttttcta cgaccgcaa cgatccgaga accatatcca 1320
 caccagggc ctgcttgcgc tggcagccg ccacgtcgac gtctgtggg cactgctgcg 1380
 cgacaacaga acatggcaac ccagcaacc aaccgtggca gctgcctgac gcactcaccg 1440
 ggctcctca ccgcttgaca cgtcattga ga 1472

<210> 3
 <211> 1554
 <212> DNA
 <213> Mycobacterium avium

<400> 3
 cgatcatgct gtccttacct ttcttcgagg gtggtcgtgg ccgagggcct taggcttcca 60
 actgccagg gacgtcgggt atggctttca tgcgtttgcc gtctgtgatg gccgaaggag 120
 attggccgcc cagcgtcctg cgacgactcg accgctaatt gagagatgag atttgatcgc 180
 30 tgtgtaagga cagtcggcg tggctcgtctg ctgggttgat gatgacgata atgaccatgg 240
 aggtggttgt gacgcaacaa ctgtgggctg gcgttgatgc cggaaagtcc gaccaccatt 300
 gcgtggtcat cgatgcagag ggcaaccgac tgcttttcta gcggatcccc aacgatgaga 360
 gttcgtgct gcaagtgatc caggcggta cagagctggc cgatggcggc gaggtcacct 420
 gggcggtcga cctcaaccac ggcggggcg cgtgctgat caccctgctc atcactgacg 480
 accagcggct gctctatatc cctggccgca cgtctacca cgttctggc gggatcgcg 540
 35 gcgatgaaa gaccgacgcc aaagacgtg cgtgatcgc cgatcaggcc cggatgcgcc 600
 gcgatctgca accactgccc cctggcgacg agatcgccgt ggacctgccc atcctgaccg 660
 cccgacgcag cgatctggtc gccgatcgca cccggcgcat caaccggctg cgcgccagc 720
 tgctggaata ctccccgcc ctggaacgtg cctttgacta cagctccagc aaggccgcgc 780
 tgatctgct caccgggtac caaactccc atggattgag ccgtgcccgg gtcacccgac 840
 ttgcggcctg gctgcgtaaa cgcaaggccc gcaatgctga tgggtgggca gctgcggcga 900
 40 tcgagggcgc caacgccccaa cacacgatag ttcccgcca acaactggcc gccgcgatgg 960
 tggcgccgct ggctaaggag gtgatgacc tcgacaccga aatcgcgcc accgacgtga 1020
 tgatcgagga ccgatttcgc cgccaccgcc acgcccagat catcctgagc atgcccggct 1080
 tcggcgctcat actcggcgct gaatttctcg ccgccaccgg aggcgacatg accgcctttg 1140
 acagcgtcga tcgcttggc ggctctcgc ggctggcccc ggtaccgcca gactccggac 1200
 45 gcatcagcgg caacctcaaa cgccccgcc gctacgaccg acgactgctg cgacctgct 1260
 acctgtcggc ccaaatcgcc atccgaccg acccgcttc gcgcacctac tacgaccgca 1320
 aacgcgctga aggcaaaacc cataccaaag ccgtcctcgc cctggccccg cgacgcctca 1380
 acgtcttgtg ggccatgctg cgcgaccacg ctgtctacca cccgcaacc actactgcgg 1440
 ctgcttgaca acgtcattga gaatctcctt cgatggctgc tgcggtggcc aatggttcac 1500
 cggatgctcg agagtggctc aaaggtattg cgtggcatag gaacgccagg gccg 1554

<210> 4
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 5
 <400> 4
 cttacctttc ttgaagggtg ttc 23
 <210> 5
 10 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 <400> 5
 gtatggcttt catgtggtg ct 22
 20 <210> 6
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 <400> 6
 30 acctttcttg aagggtgttc gg 22
 <210> 7
 <211> 22
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 40 <400> 7
 cctttcttga aggggtgtcg gg 22
 <210> 8
 45 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:
 50 M.paratuberculosis IS900-based sense primers
 <400> 8
 ggctttcatg tgggtgctgt gtt 23
 55 <210> 9

<211> 23
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 <400> 9
 10 gctttcatgt ggttgctgtg ttg 23
 <210> 10
 <211> 23
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 20 <400> 10
 ctttcatgtg gttgctgtgt tgg 23
 <210> 11
 25 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 30 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 <400> 11
 gtcgtctgct gggttgatct g 21
 35 <210> 12
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 <400> 12
 45 tcgtctgctg ggttgatctg g 21
 <210> 13
 <211> 24
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers
 55 <400> 13

ttgatctgga caatgacggt tacg 24

5 <210> 14
 <211> 21
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers

<400> 14
 aggtggttgt ggcacaacct g 21

15 <210> 15
 <211> 21
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers

25 <400> 15
 gtggttgtgg cacaacctgt c 21

30 <210> 16
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers

35 <400> 16
 atggttatta acgacgacga gc 22

40 <210> 17
 <211> 22
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence:
 M.paratuberculosis IS900-based sense primers

<400> 17
 ggttattaac gacgacgcgc ag 22

50 <210> 18
 <211> 20
 <212> DNA
 <213> Artificial Sequence

55 <220>

<223> Description of Artificial Sequence:
M.paratuberculosis IS900-based sense primers

5 <400> 18
cgcqctgctg gagttgattg 20

10 <210> 19
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Description of Artificial-Sequence:
M.paratuberculosis IS900-based sense primers

<400> 19
gcgctgctgg agttgattgc . 20

20 <210> 20
 <211> 18
 <212> DNA
 <213> Artificial Sequence

25 <223> Description of Artificial Sequence:
M.paratuberculosis IS900-based sense primers

<400> 20
ggcgatcgac ctcaacgc 18

```
<210> 21
<211> 19
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence:
M.paratuberculosis IS900-based sense primers

<400> 21
cgccaaagac gctgcatc 19

```

45      <210> 22
        <211> 20
        <212> DNA
        <213> Artificial Sequence

```

<220>
<223> Description of Artificial Sequence:
M.paratuberculosis IS900-based sense primers

<400> 22
gagctgcgca tcttgaccag 20

55 <210> 23
 <211> 20


```

5      <210> 28
      <211> 24
      <212> DNA
      <213> Artificial Sequence

      <220>
      <223> Description of Artificial Sequence:
10      M.paratuberculosis IS900-based anti-sense primers

      <400> 28
      tcgctcgtaa taaccatgca gtaa 24

15      <210> 29
      <211> 20
      <212> DNA
      <213> Artificial Sequence

      <220>
      <223> Description of Artificial Sequence:
20      M.paratuberculosis IS900-based anti-sense primers

      <400> 29
      atcgcgcgcg gtcgctcgta 20

25      <210> 30
      <211> 20
      <212> DNA
      <213> Artificial Sequence

30      <220>
      <223> Description of Artificial Sequence:
      M.paratuberculosis IS900-based anti-sense primers

      <400> 30
35      caatcaactc cagcagcgcg 20

      <210> 31
      <211> 19
      <212> DNA
      <213> Artificial Sequence

40      <220>
      <223> Description of Artificial Sequence:
      M.paratuberculosis IS900-based anti-sense primers

45      <400> 31
      cgtcaccgcc gcaatcaac 19

      <210> 32
      <211> 21
      <212> DNA
      <213> Artificial Sequence

50      <220>
      <223> Description of Artificial Sequence:
55

```


M.paratuberculosis IS900-based anti-sense primers

5 <400> 32
 gaatataaag cagccgctgc c 21

```

      <210> 33
      <211> 18
      <212> DNA
10    <213> Artificial Sequence

```

<220>
<223> Description of Artificial Sequence:
M.paratuberculosis IS900-based anti-sense primers

15 <400> 33
ggcctgatcg gcgatgat 18

20 <210> 34
 <211> 20
 <212> DNA
 <213> Artificial Sequence

25 <223> Description of Artificial Sequence:
M.paratuberculosis IS900-based anti-sense primers

<400> 34
gcagctcgac tgcgatgtca 20

30 <210> 35
 <211> 20
 <212> DNA
 <213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence:
M.paratuberculosis IS900-based anti-sense primers

```

<400> 35
accagatcgg aacgtcggct

```

```

    <210> 36
    <211> 22
    <212> DNA
    <213> Artificial Sequence

```

<220>
<223> Description of Artificial Sequence:
M.paratuberculosis IS900-based anti-sense primers

<400> 36
gtcgggagtt tggtagccag ta 22

55. $\langle 210 \rangle$ 37
 $\langle 211 \rangle$ 18
 $\langle 212 \rangle$ DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

M.paratuberculosis IS900-based anti-sense primers

<400> 37

acgcggctac tcgagcgc

18

<210> 38

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

M.paratuberculosis IS900-based anti-sense primers

<400> 38

gctgcgacgg tatcggcg

18

Claims

1. An oligonucleotide corresponding in sequence to a part of SEQ ID NO. 1 or to its complementary sequence, wherein the oligonucleotide has:

- a) a length of 18 to 24 nucleotides;
- b) a G/C content of 37% to 70%
- c) a melting temperature of 55 - 65 °C;
- d) no more than 5 contiguously repeated bases;
- e) no more than 7 contiguous G and/or C residues;
- f) a total number of G and C residues of 9 to 13; and
- g) at least two mismatches with SEQ ID NO. 2 and with SEQ ID NO. 3, of which at least one mismatch with each SEQ ID NO. 2 and SEQ ID NO. 3 occurs in the three most extreme nucleotides at its 3'-end.

2. An oligonucleotide according to claim 1, wherein the oligonucleotide has at least four mismatches with SEQ ID NO. 2 and with SEQ ID NO. 3, of which at least two mismatches with each SEQ ID NO. 2 and SEQ ID NO. 3 occur in the three most extreme nucleotides at its 3'-end, of which at least one mismatch with either SEQ ID NO. 2 or SEQ ID NO. 3 occurs at the most extreme nucleotide at its 3'-end.

3. An oligonucleotide according to claims 1 or 2, wherein the oligonucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 25, SEQ ID NO. 26, SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 29, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 32, SEQ ID NO. 33, SEQ ID NO. 34, SEQ ID NO. 35, SEQ ID NO. 36, SEQ ID NO. 37, SEQ ID NO. 38

4. A method for the detection of *M.avium* ssp. *paratuberculosis* in a sample, wherein the method comprises the step performing a PCR on the sample, wherein a first and a second oligonucleotide according to any one of claims 1 to 3 are used as PCR primers, of which the first oligonucleotide is of the same orientation as SEQ ID NO. 1 and is located upstream of the second oligonucleotide with respect to SEQ ID NO. 1 and of which the second oligonucleotide is complementary to SEQ ID NO. 1.

5. A method according to claim 4, wherein the method further comprises the step of performing a second PCR wherein a reaction product obtained in claim 4 is used as template and wherein a third and a fourth oligonucleotide according to any one of claims 1 to 3 are used as PCR primers, of which the third oligonucleotide is of the same orientation as SEQ ID NO. 1 and is located downstream of the first oligonucleotide, upstream of the second oligonucleotide and upstream of the fourth oligonucleotide with respect to SEQ ID NO. 1, and of which the fourth oligonucleotide is complementary to SEQ ID NO. 1 and is located upstream of the second oligonucleotide with respect to SEQ ID NO. 1.

6. A method according to claims 4 or 5, wherein the method further comprises the step of detecting the presence or absence of an amplified DNA fragment.

7. A method according to any one of claims 4 to 6, wherein the sample is milk.

8. A method according to any one of claims 4 to 7, wherein the sample is milk from a mammal selected from the group consisting of human, bovine, ovine, caprine, equine.

9. A method according to any one of claims 7 to 8, wherein the template DNA is extracted from the milk prior to amplification.

10. A kit for use in the methods of any one of claims 4 to 9, wherein the kit comprises at least two oligonucleotides according to any one of claim 1 to 3, of which a first oligonucleotide is of the same orientation as SEQ ID NO. 1 and is located upstream from a second oligonucleotide with respect to SEQ ID NO. 1 and wherein the second oligonucleotide is complementary to SEQ ID NO. 1, and wherein the kit may optionally comprise further components for kits known per se.

11. A kit according to claim 10, wherein the kit further comprises a third and a fourth oligonucleotides according to any one of claim 1 to 3, of which the third oligonucleotide is of the same orientation as SEQ ID NO. 1 and is located downstream of the first oligonucleotide, upstream of the second oligonucleotide and upstream of the fourth oligonucleotide with respect to SEQ ID NO. 1; and of which the fourth oligonucleotide is complementary to SEQ ID NO. 1.

5

10

15

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 20 0057

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	VARY P H ET AL: "USE OF HIGHLY SPECIFIC DNA PROBES AND THE POLYMERASE CHAIN REACTION TO DETECT MYCOBACTERIUM PARATUBERCULOSIS IN JOHNE'S DISEASE" JOURNAL OF CLINICAL MICROBIOLOGY, US, WASHINGTON, DC, vol. 28, no. 5, 1 May 1990 (1990-05-01), pages 933-937, XP000619662 ISSN: 0095-1137	1	C12Q1/68
Y	* the whole document *	2-11	
X	WO 92 11390 A (IDEXX LAB INC) 9 July 1992 (1992-07-09)	1	
Y	* the whole document *	2-11	
Y	EP 0 754 700 A (CRUACHEM LTD) 22 January 1997 (1997-01-22)	1-11	
Y	MILLAR DOUGLAS ET AL: "IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows' milk in England and Wales." APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 62, no. 9, 1996, pages 3446-3452, XP002173058 ISSN: 0099-2240	1-11	
	* the whole document *		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12Q
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 27 July 2001	Examiner Hagenmaier, S
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 03/02 (P04C01)



European Patent
Office

Application Number

EP 01 20 0057

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☒ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 20 0057

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	ELLINGSON J L E ET AL: "Evaluation of the accuracy and reproducibility of a practical PCR panel assay for rapid detection and differentiation of Mycobacterium avium subspecies." MOLECULAR AND CELLULAR PROBES, vol. 14, no. 3, June 2000 (2000-06), pages 153-161, XP002173059 ISSN: 0890-8508 * the whole document *	1-11	
Y	FIDLER H M ET AL: "Specific detection of Mycobacterium paratuberculosis DNA associated with granulomatous tissue in Crohn's disease." GUT, vol. 35, no. 4, 1994, pages 506-510, XP001002882 ISSN: 0017-5749 * the whole document *	1-11	
Y	NEWTON: "PCR" 1994, SPEKTRUM, AKAD. VERL. XP002173062 See page 41-page 43	1-11	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	WO 93 09251 A (PASTEUR INSTITUT) 13 May 1993 (1993-05-13) * the whole document *	1-11	
A	DATABASE EMBL 'Online! ID: MPIS900A, 1989 GREEN: "Mycobacterium paratuberculosis insertion element IS900" XP002173063 * abstract *		
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 27 July 2001	Examiner Hagenmaier, S
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (PAC01)



European Patent
Office

**LACK OF UNITY OF INVENTION
SHEET B**

Application Number
EP 01 20 0057

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-11 (all partially)

Invention 1:

Oligonucleotide with Seq.ID 4 and methods for detection of *M.avium* ssp. paratuberculosis using said oligonucleotide and kits comprising said oligonucleotide.

2. Claims: 1-11 (all partially)

Inventions 2-35:

Oligonucleotide with Seq.ID 5 and methods for detection of *M.avium* ssp. paratuberculosis using said oligonucleotide and kits comprising said oligonucleotide.

Ibidem for Seq.IDs 6-38.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 20 0057

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	<p>DATABASE EMBL 'Online! ID: MAIS901, 1991 DALE: "Mycobacterium avium insertion element IS901 ORF" XP002173064 * abstract *</p> <p>---</p>		
A	<p>BULL TIM J ET AL: "Characterization of IS900 loci in Mycobacterium avium subsp. paratuberculosis and development of multiplex PCR typing." MICROBIOLOGY (READING), vol. 146, no. 9, September 2000 (2000-09), pages 2185-2197, XP002173061 ISSN: 1350-0872 * the whole document *</p> <p>-----</p>		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	27 July 2001	Hagenmaier, S	
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>			

EPO FORM 1503 03.82 (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 20 0057

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

27-07-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9211390 A	09-07-1992	EP 0566670 A	27-10-1993
		US 5800984 A	01-09-1998
EP 0754700 A	22-01-1997	NONE	
WO 9309251 A	13-05-1993	FR 2683227 A	07-05-1993
		AT 136592 T	15-04-1996
		CA 2122367 A	13-05-1993
		DE 69209846 D	15-05-1996
		DE 69209846 T	14-11-1996
		EP 0612356 A	31-08-1994
		ES 2088660 T	16-08-1996
		GR 3020265 T	30-09-1996
		JP 7500502 T	19-01-1995
		US 5650272 A	22-07-1997

EPO FORM P0439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82